Supernus Inc (SUPN) Stock Forecast & Price Target

Supernus is viewed positively because the merger created an 11-therapy CNS franchise with multiple growth engines in ADHD, Parkinson’s disease, postpartum depression, and opioid use disorder, reducing single-product risk and improving commercial durability. Its outlook is further strengthened by Sublocade’s differentiated monthly dosing, ~76% share of the U.S. LAI buprenorphine market, and management’s 2026 revenue guidance being raised to $1.01–$1.05B, while Qelbree and Zurzuvae continue to post double-digit prescription growth. With EBITDA expected to exceed $1B in 2027, net debt just north of ~$800M, and meaningful operating leverage from ~\$120M of annualized SG&A savings, the company appears positioned for stronger margins, more M&A flexibility, and multiple expansion.

Supernus is facing a weak fundamental setup because its key growth drivers are exposed to generic erosion, payer pressure, and patent risk, with Qelbree modeled to grow more modestly and Gocovri set for LOE in mid-2029 after peaking at just over $175M in 2028. The broader OUD market context is also unfavorable: long-acting injectables remain only an 8-9% niche, the film still held ~14.2% of the U.S. buprenorphine market in 2025 despite 4 generic competitors, and management expects continued share erosion as competition persists. On top of that, Supernus’s pipeline carries clinical and regulatory uncertainty, while future commercialization may require new partnerships or financings, limiting confidence in durable earnings power.